S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,031.91 (-0.39%)
DOW   37,678.25 (-0.32%)
QQQ   429.40 (-0.39%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Xencor (XNCR) Competitors

$19.17
+0.25 (+1.32%)
(As of 11:33 AM ET)

XNCR vs. OCUL, COLL, PRTA, MIRM, ABCL, DCPH, CNTA, IMNM, MNKD, and KNSA

Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Ocular Therapeutix (OCUL), Collegium Pharmaceutical (COLL), Prothena (PRTA), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Deciphera Pharmaceuticals (DCPH), Centessa Pharmaceuticals (CNTA), Immunome (IMNM), MannKind (MNKD), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical preparations" industry.

Xencor vs.

Ocular Therapeutix (NASDAQ:OCUL) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.

In the previous week, Ocular Therapeutix had 9 more articles in the media than Xencor. MarketBeat recorded 15 mentions for Ocular Therapeutix and 6 mentions for Xencor. Xencor's average media sentiment score of 0.73 beat Ocular Therapeutix's score of 0.24 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
6 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Xencor
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ocular Therapeutix has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

59.2% of Ocular Therapeutix shares are held by institutional investors. 5.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 5.0% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ocular Therapeutix currently has a consensus price target of $16.80, suggesting a potential upside of 115.66%. Xencor has a consensus price target of $36.00, suggesting a potential upside of 90.27%. Given Xencor's stronger consensus rating and higher probable upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Xencor
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Xencor received 68 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. Likewise, 72.85% of users gave Xencor an outperform vote while only 69.69% of users gave Ocular Therapeutix an outperform vote.

CompanyUnderperformOutperform
Ocular TherapeutixOutperform Votes
423
69.69%
Underperform Votes
184
30.31%
XencorOutperform Votes
491
72.85%
Underperform Votes
183
27.15%

Ocular Therapeutix has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$58.44M19.81-$80.74M-$1.25-6.23
Xencor$168.34M6.87-$126.09M-$2.10-9.01

Xencor has a net margin of -74.90% compared to Xencor's net margin of -138.15%. Ocular Therapeutix's return on equity of -18.67% beat Xencor's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-138.15% -321.12% -53.93%
Xencor -74.90%-18.67%-15.23%

Summary

Ocular Therapeutix beats Xencor on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XNCR vs. The Competition

MetricXencorPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.16B$6.61B$4.74B$7.49B
Dividend YieldN/A3.13%5.51%3.96%
P/E Ratio-9.0117.26262.8019.08
Price / Sales6.87319.382,511.6487.71
Price / CashN/A20.3433.8528.11
Price / Book1.725.084.684.27
Net Income-$126.09M$148.85M$101.04M$211.64M
7 Day Performance-6.66%-5.27%-4.00%-3.77%
1 Month Performance-18.06%-5.97%-3.67%-2.69%
1 Year Performance-36.72%-2.22%11.47%5.85%

Xencor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCUL
Ocular Therapeutix
3.6759 of 5 stars
$7.79
-0.1%
$16.80
+115.7%
+48.1%$1.16B$58.44M-6.23267Analyst Report
News Coverage
COLL
Collegium Pharmaceutical
2.5887 of 5 stars
$35.40
+0.7%
$39.00
+10.2%
+54.4%$1.16B$566.77M30.00197
PRTA
Prothena
2.8521 of 5 stars
$21.34
-3.0%
$69.63
+226.3%
-57.7%$1.15B$91.37M-7.62173News Coverage
MIRM
Mirum Pharmaceuticals
3.7722 of 5 stars
$24.01
+0.4%
$52.11
+117.0%
-3.9%$1.13B$186.37M-6.05264News Coverage
ABCL
AbCellera Biologics
1.3995 of 5 stars
$4.05
-3.1%
$15.86
+291.5%
-45.1%$1.19B$38.03M-7.79586Positive News
Gap Up
DCPH
Deciphera Pharmaceuticals
3.0338 of 5 stars
$14.84
-0.4%
$23.00
+55.0%
+2.1%$1.20B$163.36M-6.48355Short Interest ↑
CNTA
Centessa Pharmaceuticals
0.5879 of 5 stars
$11.03
+2.3%
$10.00
-9.3%
+174.4%$1.11B$6.85M-7.0375Short Interest ↑
IMNM
Immunome
1.691 of 5 stars
$18.40
-2.4%
$32.67
+77.5%
+281.7%$1.10B$14.02M-3.4137Analyst Report
MNKD
MannKind
2.3155 of 5 stars
$4.05
-1.7%
$8.00
+97.5%
+0.5%$1.10B$198.96M-81.00411Positive News
KNSA
Kiniksa Pharmaceuticals
3.0183 of 5 stars
$17.46
+0.1%
$30.00
+71.8%
+53.8%$1.23B$270.26M97.01297Short Interest ↑
News Coverage

Related Companies and Tools

This page (NASDAQ:XNCR) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners